Fig. 1.
Patient enrollment and allocation to the remote ischemic preconditioning (RIPC) and control (Sham-RIPC) arms. The first part (light blue box) shows the recruitment of the initial RenalRIP trial,9 while the second part (dark blue box) shows the analyzed cohort of this follow-up analysis. MAKE90+ = patients meeting the endpoint major adverse kidney events; MAKE90− = patients not meeting the endpoint major adverse kidney events.